Scientific Advisory Committee
Alejandro Alagón Cano
Alejandro Alagón Cano is a surgeon, with a Master’s Degree and PhD in Basic Biomedical Research from the National Autonomous University of Mexico (UNAM). He carried out a post-doctoral research at Rockefeller University in New York, USA, and is currently a full time Grade C Tenured Researcher in the Department of Molecular Medicine and Bioprocesses at the UNAM Institute of Biotechnology. Dr. Alagón is a lecturer on the UNAM Biochemical Sciences Masters and PhD programs. He is the author of more than 100 articles, most of which were published in journals with an international circulation, with more than 900 citations.
He is also known for his seminal contribution to the discovery and development of the fibrinolytic agent Desmoteplase. From 1994 onwards, he has been working in close collaboration with the Bioclon Institute in Mexico City, to develop highly refined and pure antivenins, significantly reducing the adverse effects previously shown by these substances. These new antivenins are used in more than ten countries. He has also developed rapid diagnostic tests for Laboratorios Silanes in Mexico, some of which are already on the market. In 2004, he was awarded the National University Award in the field of Technological Innovation and Industrial Design. The following year, he received the 2005 National Prize for Arts and Sciences, the highest distinction awarded by the Mexican government.
Mercè Boada has a PhD in Medicine from the Autonomous University of Barcelona, and is a specialist in Neurology. She is also Medical Director at the Fundació ACE. Institut Català de Neurociències Aplicades (Catalan Institute of Applied Neurosciences, Alzheimer Center Research and Memory Clinic) and Head of the Neurology Service Department, within the Department of Neurodegenerative Diseases, at the Vall d’Hebron Hospital, Barcelona.
She is the Principal Investigator in many studies focusing on the genomics and phenomics of common diseases, biomarkers and neuroimaging for prodromal AD diagnosis, and design of new AD treatments. She is Co-researcher of the “i-habilitación” translational technology and communication project, and leads the “Documento Sitges” project concerning legal rights and protection for people with dementia. She is a member of the European Alzheimer’s Disease Consortium (EADC), Co-director of the Barcelona-Pittsburgh Biannual Conference, and member of the following scientific societies: SCN, SEN, AAN, ANA. She received the 2008 Professional Excellence Award from the Medical Council of Catalonia.
Ángel Cedazo-Mínguez graduated from the University of Salamanca (Spain) with a Masters in Biology. He currently works at the Karolinska Institute in Stockholm (Sweden), where he is Co-director of the Alzheimer’s Disease Research Centre, and Vice-head of the Department of Neurobiology, Care Sciences and Society at the Karolinska Institute (Sweden).
From 1994 to 1997, he worked in a collaborative project with Pharmacia/PharmaItalia, to identify modulators of beta-amyloid production. He obtained a PhD in Medicine from the Karolinska Institute (Sweden) in 2002, and was appointed Associate Professor in 2009. He currently leads a research group focused on the molecular mechanisms behind the pathogenesis of Alzheimer’s disease.
Ana Martínez has a PhD in Organic Chemistry from the Madrid Complutense University. She is currently a research professor at the Medicinal Chemistry Institute of the Spanish National Research Council (CSIC), where she has been carrying out her research work since 1985. For the past few years, her scientific interest has been focused on neurodegenerative diseases, leading numerous research projects in medicinal chemistry and rational design of drugs for new therapies for Alzheimer’s and Parkinson’s disease, amyotrophic lateral sclerosis, spinal cord trauma and multiple sclerosis.
In order to complete the transfer process of her technology, she was R&D Director for the company NeuroPharma (now NOSCIRA) from February 2002 until January 2008. Here, she carried out the necessary measures to bring two of her research compounds, known as NP-12 and NP-61, into clinical trials. These are currently in Phase II and Phase I of clinical trials respectively, as modifying agents for Alzheimer’s disease. She is author of more than 150 scientific publications, more than 20 active patents in the field, and editor of several books related to Alzheimer’s disease. She has also completed the Management Development Program at the IESE Business School.
Carlos Saura obtained a Doctorate in Chemical Sciences from the University of Barcelona in 1998. He has undertaken post-doctoral research at Johns Hopkins University, the University of Chicago, and Harvard Medical School, where he studied the genetic basis of Alzheimer’s disease. He is currently a university lecturer and a researcher in the areas of Biochemistry and Molecular Biology, at the Neurosciences Institute of the Autonomous University of Barcelona.
Dr. Saura has been leading his own translational biomedical research group at the Autonomous University of Barcelona since 2004. He is a pioneer in Spain in the generation and characterization of knockout and transgenic mouse models of Alzheimer’s disease. His research has contributed to shedding light on the molecular mechanisms involved in synaptic dysfunction and neurodegeneration in experimental models of this disease.